undamentalytics Newsletter
Sign in

Stoke Therapeutics, Inc. (STOK) stock

Add to watchlist

Add holding +

NASDAQ: STOK Nasdaq Biotechnology Next results ~January 11, 2027

D Fundamentals grade

Stoke Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Stoke Therapeutics, Inc. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: free cash flow after stock pay is not positive. We'll show the comparison once resolved.

Stoke Therapeutics, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 8 selling0 purchases and 83 sales by directors and officers, last 12 monthsInsider trades
  • Funds102 adding, 84 cuttingOf 36 active managers that changed their stake, 23 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Stoke Therapeutics files

Where Stoke Therapeutics stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $28m, down 86.2% on a year earlier, a steeper fall than the 83.2% decline a quarter earlier. That puts it 48 of 49 for growth among the biotechnology companies we cover. Free-cash-flow margin fell to -654.9% from 30.6% a year earlier. Operating margin narrowed to -809.7% from 20.2%. The diluted share count is up 7.1% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades E. It passes 2 of our 3 financial-health checks.

Our model value for Stoke Therapeutics is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 3, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~January 11, 2027 (estimated)

Stoke Therapeutics, Inc.'s trailing-twelve-month revenue fell 86.2% year on year, with a free-cash-flow margin of -654.9%. Where it lags: revenue growth of -86.2% ranks 160 of 172 biotechnology companies we cover.

Current signal Revenue growth decelerating: TTM revenue growth slowed to -86.2% (-3.0pp vs the prior quarter), the 5th consecutive quarterly slowdown.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.1bn.

Things to watch

  • Revenue shrinking. Revenue fell 86.2% over the last 12 months.
  • Loss-making. Operating margin is -809.7%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 829.8 points on a year ago.
  • Burning cash. Free cash flow was -654.9% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 135.7% of revenue, against a median of 19.2% for biotechnology companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 7.1% in a year.

Latest results: FY2026 Q2

Filed August 3, 2026
Earnings per share
-$1.08 against an average estimate of -$0.91: missed by 18.1%
Revenue
$9m, down 32.5% on a year earlier
Share reaction
-0.5% in the first session after the results on October 29, 2026, against -2.1% for the S&P 500
Next report
October 29, 2026; average EPS estimate -$0.97

Stoke Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+0.7%
  • 1 week+4.0%
  • 1 month+3.4%
  • This year-16.6%
  • 1 year-11.9%
  • 5 years-0.4%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$27.6M
Operating margin
-809.7%
Net margin
-753.6%
EPS (TTM, diluted)
$-3.35

Growth

Revenue growth
−86.2%
Change in growth rate
−3.0 pts
Share count change
+7.1%

Cash

Free cash flow (TTM)
-$181M
FCF margin
-654.9%
Stock pay % of revenue
135.7%

Earnings

Last results
October 29, 2026
Next results (est.)
January 11, 2027

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Leadership
  3. Announcement
  4. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Stoke Therapeutics, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: free cash flow after stock pay is not positive.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Stoke Therapeutics, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.09 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$5.1 ~$4.2–$5.9 Left out: out of range vs price (0.19x)
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$2.2 ~$2.3–$8.5 Left out: out of range vs price (0.08x)
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Stoke Therapeutics, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2022202320242025Now
Share price$9.23$5.26$11.03$31.74$26.48
Market value$359m$231m$596m$1.9bn$1.6bn
+ Net debt (− = net cash)−$114m−$191m−$128m−$84m−$110m
Enterprise value$245m$40m$468m$1.8bn$1.5bn
Multiples
Price / sales 28.9x26.4x16.3x10.2x59.6x
Price / earnings —————
Price / free cash flow ———41.8x—
EV / EBITDA —————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$3.62 −2917% $32m −83%
Next −$3.53 +3% $45m +40%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +11.6% on 90 days ago. In the last 30 days, 0 analysts raised Stoke Therapeutics, Inc.'s forecast and 4 cut it.

Consensus EPS forecast Stoke Therapeutics, Inc., last 90 days
−$4.00 −$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$3.25 Current fiscal year, 60 days ago: −$3.62 Current fiscal year, 30 days ago: −$3.62 Current fiscal year, 7 days ago: −$3.62 Current fiscal year, Now: −$3.62 −$3.62 Next fiscal year, 90 days ago: −$3.08 Next fiscal year, 60 days ago: −$3.49 Next fiscal year, 30 days ago: −$3.52 Next fiscal year, 7 days ago: −$3.52 Next fiscal year, Now: −$3.53 −$3.53

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$3.25−$3.08
60 days ago −$3.62−$3.49
30 days ago −$3.62−$3.52
7 days ago −$3.62−$3.52
Now −$3.62−$3.53

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2026 −$0.91 −$1.08 −18.1%
Jun 2026 −$0.78 −$0.93 −19.1%
Mar 2026 −$0.82 −$0.79 +3.1%
Dec 2025 −$0.74 −$0.97 −31.8%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

14 analysts, Oct 2026
Buy14100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202621214
  2. Sep 202621214
  3. Aug 202621214
  4. Jul 202611213

Counts of recommendations published by analysts covering Stoke Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
16.5%
of tradable shares
Days to cover
10.28
at average volume
Short interest, 1 month
−8%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
3.7%
of shares
Employees
170
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

What moved the share price

Last 12 months −11.9%

$30.04 on October 31, 2025 to $26.48

ThenNowEffect
Revenue (last 12 months) $200m $28m −86.2%
P/S multiple 8.7x 59.6x +584.0%
Share count 58m 62m −6.6%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

Last 3 years +521.6%

$4.26 on November 3, 2023 to $26.48

ThenNowEffect
Revenue (last 12 months) $9m $28m +211.9%
P/S multiple 19.9x 59.6x +198.7%
Share count 41m 62m −33.3%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
STOK−61%−62%−43%+110%+188%−17%
Industry peers (median)−35%−56%−17%−29%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
STOK17%58%33%42%75%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
STOK−74%−73%−76%−38%−54%−41%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since June 19, 2019: 95% from January 19, 2021 to October 27, 2023. Getting back needed a 1972% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$22.37 – $38.35
From 52-week high
−31.0%
vs 50-day average
−3.0%
vs 200-day average
−14.3%
Volatility (1 year)
56%
Beta vs S&P 500
0.80

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 8 down
typical move ±11.7%
After a week
5 up, 6 down
typical move ±19.1%
After a month
7 up, 4 down
typical move ±26.3%
Results releasedNext dayS&P 500 next day5 days21 days
October 29, 2026 −0.5% −2.1% — —
August 3, 2026 +9.7% +3.3% +11.7% +7.0%
May 7, 2026 −1.2% +0.5% −5.8% −12.9%
January 12, 2026 −6.9% 0.0% −12.6% −1.9%
November 4, 2025 −12.6% −0.8% −3.8% +19.0%
August 12, 2025 +28.5% +1.4% +40.5% +81.5%
May 13, 2025 −6.9% +0.8% +4.0% +22.4%
March 18, 2025 −8.2% 0.0% −14.0% −16.0%
November 5, 2024 +1.1% +3.7% +4.0% −4.0%
August 7, 2024 −0.6% +1.6% −1.8% +3.3%
May 6, 2024 −0.7% +1.1% −3.9% +36.5%
March 25, 2024 +63.3% −0.5% +107.6% +85.1%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Stoke Therapeutics, Inc. in five measures

Fundamentals grade D
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Stoke Therapeutics, Inc.
$0 $100M $200M $300M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $9.2M Revenue (TTM), FY23 Q4: $8.8M Revenue (TTM), FY24 Q1: $7.8M Revenue (TTM), FY24 Q2: $15.2M Revenue (TTM), FY24 Q3: $16.7M Revenue (TTM), FY24 Q4: $36.6M Revenue (TTM), FY25 Q1: $190.9M Revenue (TTM), FY25 Q2: $199.9M Revenue (TTM), FY25 Q3: $205.6M Revenue (TTM), FY25 Q4: $184.4M Revenue (TTM), FY26 Q1: $32.1M Revenue (TTM), FY26 Q2: $27.6M $27.6M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $9.2M
FY23 Q4 $8.8M
FY24 Q1 $7.8M
FY24 Q2 $15.2M
FY24 Q3 $16.7M
FY24 Q4 $36.6M
FY25 Q1 $190.9M
FY25 Q2 $199.9M
FY25 Q3 $205.6M
FY25 Q4 $184.4M
FY26 Q1 $32.1M
FY26 Q2 $27.6M
Revenue growth, TTM YoY Stoke Therapeutics, Inc.
-1000% 0% 1000% 2000% 3000% FY23 Q4 FY24 Q2 FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 Revenue growth, TTM YoY, FY23 Q4: -29.2% Revenue growth, TTM YoY, FY24 Q1: -46.1% Revenue growth, TTM YoY, FY24 Q2: 71.4% Revenue growth, TTM YoY, FY24 Q3: 81.1% Revenue growth, TTM YoY, FY24 Q4: 316.3% Revenue growth, TTM YoY, FY25 Q1: 2333.5% Revenue growth, TTM YoY, FY25 Q2: 1218.8% Revenue growth, TTM YoY, FY25 Q3: 1128.2% Revenue growth, TTM YoY, FY25 Q4: 404.5% Revenue growth, TTM YoY, FY26 Q1: -83.2% Revenue growth, TTM YoY, FY26 Q2: -86.2% -86.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 -29.2%
FY24 Q1 -46.1%
FY24 Q2 71.4%
FY24 Q3 81.1%
FY24 Q4 316.3%
FY25 Q1 2333.5%
FY25 Q2 1218.8%
FY25 Q3 1128.2%
FY25 Q4 404.5%
FY26 Q1 -83.2%
FY26 Q2 -86.2%
Operating margin (TTM) Stoke Therapeutics, Inc.
-2000% -1500% -1000% -500% 0% 500% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -1215.1% Operating margin (TTM), FY23 Q4: -1307.0% Operating margin (TTM), FY24 Q1: -1509.9% Operating margin (TTM), FY24 Q2: -755.7% Operating margin (TTM), FY24 Q3: -700.6% Operating margin (TTM), FY24 Q4: -277.3% Operating margin (TTM), FY25 Q1: 20.0% Operating margin (TTM), FY25 Q2: 20.2% Operating margin (TTM), FY25 Q3: 13.2% Operating margin (TTM), FY25 Q4: -11.2% Operating margin (TTM), FY26 Q1: -577.5% Operating margin (TTM), FY26 Q2: -809.7% -809.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -1215.1%
FY23 Q4 -1307.0%
FY24 Q1 -1509.9%
FY24 Q2 -755.7%
FY24 Q3 -700.6%
FY24 Q4 -277.3%
FY25 Q1 20.0%
FY25 Q2 20.2%
FY25 Q3 13.2%
FY25 Q4 -11.2%
FY26 Q1 -577.5%
FY26 Q2 -809.7%
FCF margin (TTM) Stoke Therapeutics, Inc.
-1500% -1000% -500% 0% 500% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -914.8% FCF margin (TTM), FY23 Q4: -941.6% FCF margin (TTM), FY24 Q1: -1092.9% FCF margin (TTM), FY24 Q2: -531.9% FCF margin (TTM), FY24 Q3: -505.9% FCF margin (TTM), FY24 Q4: -238.1% FCF margin (TTM), FY25 Q1: 36.2% FCF margin (TTM), FY25 Q2: 30.6% FCF margin (TTM), FY25 Q3: 25.5% FCF margin (TTM), FY25 Q4: 24.4% FCF margin (TTM), FY26 Q1: -460.4% FCF margin (TTM), FY26 Q2: -654.9% -654.9%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -914.8%
FY23 Q4 -941.6%
FY24 Q1 -1092.9%
FY24 Q2 -531.9%
FY24 Q3 -505.9%
FY24 Q4 -238.1%
FY25 Q1 36.2%
FY25 Q2 30.6%
FY25 Q3 25.5%
FY25 Q4 24.4%
FY26 Q1 -460.4%
FY26 Q2 -654.9%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 12 9 37 184 28
EBITDA −103 −112 −99 −19 −222
Operating income −104 −115 −101 −21 −223
Net income −101 −105 −89 −7 −208
Diluted EPS −$2.60 −$2.38 −$1.65 −$0.12 −$3.35
Growth (year on year)
Revenue — −29.2% +316.3% +404.5% −86.2%
EBITDA — — — — −624.3%
Operating income — — — — −654.5%
Net income — — — — −496.1%
Diluted EPS — — — — −469.9%
Margins
EBITDA margin −828.8% <−999% −271.4% −10.2% −803.4%
Operating margin −841.2% <−999% −277.3% −11.2% −809.7%
Net margin −814.7% <−999% −243.4% −3.7% −753.6%
Free-cash-flow margin −288.8% −941.7% −238.1% 24.4% −654.9%
Cash flow
Cash from operations −32 −81 −87 46 −178
Capital spending 4 2 0 1 3
Free cash flow −36 −83 −87 45 −181
Stock-based pay 23 25 27 32 37
Free cash flow after stock pay −59 −108 −115 13 −218
Balance sheet
Cash 114 191 128 84 110
Total debt 0 0 0 0 0
Net debt (negative = net cash) −114 −191 −128 −84 −110
Diluted shares 39m 44m 54m 59m 62m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 3 checks passed · June 30, 2026
What it owns · $394m
Short-term assets $323mLonger-term assets $71m
What it owes, and who funded it · $394m
Short-term liabilities $42mLonger-term liabilities $6mShareholders' equity $346m
  • Short-term assets cover short-term liabilities $323m of assets due within a year against $42m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $323m short-term assets against $6m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$223m against $46,000 of interest.

From Stoke Therapeutics, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+7.1%
year over year
R&D spending
611.0%
of revenue
Sales & admin spending
298.7%
of revenue
Days sales outstanding
95 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated STOK GLUE TNXP ARCT ABEO CRSP Median
Revenue, last 12 months $28m $29m $29m $29m $26m $25m $56m
Revenue growth, last 12 months −86.2% −83.9% 196.0% −76.0% −87.7% −34.3% 12.6%
Revenue growth, 3-year average 46.1% — — −51.9% 212.0% −47.1% 13.7%
Revenue growth, latest quarter −32.5% −61.3% 577.9% −89.5% >999% >999% 10.2%
Gross margin — — 83.8% — 67.1% — 82.9%
Operating margin −809.7% −633.0% −568.4% −348.3% −327.6% <−999% −189.4%
Operating margin, 3-year average −515.1% <−999% −881.2% −154.0% <−999% <−999% −363.5%
Net margin −753.6% −560.8% −548.6% −317.6% −246.4% <−999% −169.8%
Cash from operations / revenue −645.2% −83.8% −525.7% −247.7% −299.5% <−999% −168.0%
Free-cash-flow margin −654.9% −111.7% −543.3% −248.0% −319.5% <−999% −162.4%
Free-cash-flow margin, 3-year average −385.4% −424.9% −605.0% −114.9% <−999% −793.9% −310.0%
Stock pay / revenue 135.7% 71.7% 27.3% 71.9% 45.4% 276.8% 20.0%
Change in share count 7.1% 11.9% — 3.5% 36.6% 10.0% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth -86.2% 12.6% 160 of 172
Change in growth rate Growth -3.0pp -0.1pp 101 of 172
Operating margin Profitability -809.7% -189.4% 133 of 175
Net margin Profitability -753.6% -157.3% 137 of 180
Free-cash-flow margin Cash generation -654.9% -145.4% 133 of 176
Stock pay as % of revenue Cash generation 135.7% 19.2% 144 of 179
Change in share count Balance sheet 7.1% 7.9% 76 of 156
Days sales outstanding Balance sheet 95 days 75 days 64 of 100

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$2.5B
Institutions reporting
197
Shares held vs prior quarter
▲ 8.8%
Positions opened / closed
27 / 27

Top buyers and sellers, Q2 2026: 102 institutions bought and 84 sold ; the biggest buyer was T. Rowe Price Investment Management, Inc (+2.2M shares) and the biggest seller Lynx1 Capital Management LP (−725K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $192M 5.9M 7.6% ▲ 9.1%
RTW Investments, LP $184M 5.6M 7.3% 0.0%
FMR LLC $174M 5.3M 6.9% ▼ 1.3%
Lynx1 Capital Management LP $132M 4.0M 5.2% ▼ 15.2%
Redmile Group, LLC $129M 3.9M 5.1% ▼ 5.2%
Wellington Management Group LLP $115M 3.5M 4.5% ▲ 13.7%
Morgan Stanley $113M 3.5M 4.5% ▲ 0.9%
Baker Bros. Advisors LP $109M 3.3M 4.3% 0.0%
Toronto Dominion Bank $104M 3.2M 4.1% 0.0%
State Street Corp $93.3M 2.9M 3.7% ▲ 25.3%
Price T Rowe Associates Inc $87.1M 2.7M 3.4% ▲ 37.6%
Vanguard Capital Management LLC $84.6M 2.6M 3.3% ▲ 9.8%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Stoke Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $8.9M 83 trades by 8 insiders · 83% under pre-set plans
Net ▼ $8.9M net selling
Insider Date Trade Shares Price Value
Allan Jonathan GENERAL COUNSEL & CORP SEC October 2, 2026 Sell pre-set plan 627 $26.33 $16,509
Ticho Barry CHIEF MEDICAL OFFICER October 1, 2026 Sell pre-set plan 1,051 $26.16 $27,494
Ticho Barry CHIEF MEDICAL OFFICER September 1, 2026 Sell pre-set plan 3,945 $30.51 $120,362
Ticho Barry CHIEF MEDICAL OFFICER September 1, 2026 Sell pre-set plan 1,600 $31.06 $49,696
Allan Jonathan GENERAL COUNSEL & CORP SEC August 18, 2026 Sell 2,716 $32.01 $86,939
Allan Jonathan GENERAL COUNSEL & CORP SEC August 18, 2026 Sell 145 $32.47 $4,708
Kaye Edward M. Md Director August 18, 2026 Sell 11,930 $32.01 $381,879
Kaye Edward M. Md Director August 18, 2026 Sell 637 $32.47 $20,683
Ticho Barry CHIEF MEDICAL OFFICER August 18, 2026 Sell 4,525 $32.01 $144,845
Ticho Barry CHIEF MEDICAL OFFICER August 18, 2026 Sell 242 $32.47 $7,858
Ticho Barry CHIEF MEDICAL OFFICER August 3, 2026 Sell pre-set plan 1,269 $29.45 $37,372
Ticho Barry CHIEF MEDICAL OFFICER August 3, 2026 Sell pre-set plan 5,907 $28.95 $171,008

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around January 11, 2027 estimated from the company's past filing pattern, not announced

  • October 29, 2026
  • August 3, 2026
  • May 7, 2026
  • January 12, 2026
  • November 4, 2025
  • August 12, 2025

Recent SEC filings

Data status

When each part of this page on Stoke Therapeutics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Stoke Therapeutics, Inc. in brief

What does Stoke Therapeutics, Inc. do?
Stoke Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Stoke Therapeutics, Inc.'s stock ticker?
Stoke Therapeutics, Inc. trades under the ticker STOK on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Stoke Therapeutics, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Stoke Therapeutics, Inc. reported revenue of $27.6M, 86.2% lower than a year earlier, according to its SEC filings.
What is Stoke Therapeutics, Inc.'s free cash flow?
Stoke Therapeutics, Inc.'s free-cash-flow margin is -654.9% of revenue over the trailing twelve months, ranking 133 of the 176 biotechnology companies we cover.
Who are Stoke Therapeutics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., RTW Investments, LP and FMR LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Stoke Therapeutics, Inc.'s market cap?
On November 2, 2026, Stoke Therapeutics, Inc.'s market capitalisation was about $1.6B and net debt of -$110M. Market figures come from third-party market data and may be delayed.
Who are Stoke Therapeutics, Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Stoke Therapeutics, Inc. are Monte Rosa Therapeutics, Inc., Tonix Pharmaceuticals Holding Corp., Arcturus Therapeutics Holdings Inc., Abeona Therapeutics Inc. and Crispr Therapeutics AG. The side-by-side comparison below sets their revenue, margins and growth against Stoke Therapeutics, Inc.'s.
Are insiders buying or selling Stoke Therapeutics, Inc. stock?
Over the last 12 months, Stoke Therapeutics, Inc.'s directors and officers reported 0 open-market purchases and 83 sales on Form 4. The insider trading page charts every trade.
When is Stoke Therapeutics, Inc.'s next earnings date?
Around January 11, 2027, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Stoke Therapeutics, Inc. announces its own schedule.